The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

In a report released yesterday, Kelly Shi from Jefferies reiterated a Buy rating on BeiGene (ONC – Research Report), with a price target of ...

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

Dubai, UAE: MSD, a leading biopharmaceutical company, has established a new office in Dubai, further solidifying its ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...